XML 29 R19.htm IDEA: XBRL DOCUMENT v3.19.2

Subsequent events	6 Months Ended
	Jun. 30, 2019
Subsequent events
Subsequent events	12.         Subsequent events The Company evaluated subsequent events through August 12, 2019, the date on which these financial statements were issued. On July 2, 2019 the Company announced the dosing of the first patient in its Phase 2a clinical trial of AKR‑001, which resulted in a $2,500 milestone obligation under the Amgen Agreement. The Company will recognize this obligation as research and development expense in its financial statements for the three months ended September 30, 2019.

X

- References

No definition available.

+ Details

Name:	us-gaap_SubsequentEventsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774

+ Details

Name:	us-gaap_SubsequentEventsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration